ALPN — Alpine Immune Sciences Share News
0.000.00%
Last trade - 00:00- $4.46bn
- $4.15bn
- $58.88m
Alpine Immune Sciences Inc expected to post earnings of 1 cents a share - Earnings Preview
Brief: Alpine Immune Sciences Reports $91 Mln Private Placement
Alpine Immune Sciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Alpine Immune Sciences Posts Qtrly Loss Per Share $0.46
Alpine Immune Sciences Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Alpine Immune Sciences Enters Into Sales Agreement With Cowen And Co
Alpine Immune up on collaboration with Merck for cancer treatment study
Brief: Alpine Immune Sciences To Collaborate With Merck On Immuno-Oncology Study To Evaluate Alpn-202 In Combination With Keytruda (Pembrolizumab)
Brief: Alpine Immune Sciences Announces First Patient Dosed In Synergy, Alpn-101 Phase 2 Lupus Clinical Trial And $45 Million In Development Milestones Achieved Under Abbvie Collaboration
Brief: Alpine Immune Sciences Set To Join Russell 3000® Index
Brief: Alpine Immune Sciences Files For Mixed Shelf Of Upto $150 Mln
Alpine Immune Sciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Alpine Immune Sciences Provides Corporate Update And Reports First Quarter 2021 Financial Results
Brief: Alpine Immune Sciences Inc Posts QTRLY Loss Per Share $0.27
U.S. RESEARCH ROUNDUP-Arrowhead Pharmaceuticals, BioTelemetry, Walmart
Brief: Alpine Immune Sciences Reports Q3 Rev Of $1.9 Mln
U.S. RESEARCH ROUNDUP-10X Genomics, Electronic Arts, Wayfair
Brief: Alpine Immune Sciences Files Prospectus Relates To Disposition From Time To Time By Selling Stockholders Of Up To 7.7 Mln Shares Of Common Stock
Brief: Alpine Immune Sciences Reports Q2 Loss Per Share Of $0.53